Business

PDMR Dealings / Market Share sale

PDMR Dealings / Market Share sale.

articleOxford Biomedica PlcFebruary 26, 20214/company/oxford-biomedica-plc/news/pdmr-dealings-market-share-sale
PDMR Dealings / Market Share sale

About this update from Oxford Biomedica Plc

[{"type":"text","content":"\n \n \n \n RNS Number : 5079Q\n Oxford Biomedica PLC\n 26 February 2021\n  \n \n \n \n  \n \n \n  \n \n \n  \n \n \n PDMR Dealings / Market Share sale\n \n \n  \n \n \n \n Oxford, UK - 26 February 2021:\n \n  \n Oxford Biomedica plc (\"Oxford Biomedica\" or \"the Group\") (LSE: OXB), a leading gene and cell therapy group, was informed on 24 February 2021, that Helen Stephenson-Ellis, Chief People Officer of the Group, exercised 1,266 DBP (2019) options at nil cost, and sold all the resulting shares at 992p. Following this transaction Helen Stephenson-Ellis holds 59,296 options and no shares in the Company.\n \n \n  \n \n \n The issued share capital of the Group is \n 82,381,687 \n ordinary 50p shares.\n \n \n  \n \n \n The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.\n \n  \n \n \n \n 1.\n \n \n Details of the Person Discharging Managerial Responsibility (\"PDMR\")/person closely associated with them (\"PCA\")\n \n \n \n \n a)\n \n \n Name\n \n \n \n Helen Stephenson-Ellis\n \n \n \n \n \n 2.\n \n \n Reason for the notification\n \n \n \n \n a)\n \n \n Position/status\n \n \n Chief People Officer\n  \n \n \n \n \n b)\n \n \n Initial notification/\n amendment\n \n \n Initial Notification\n \n \n \n \n 3.\n \n \n Details of the Issuer\n \n \n \n \n a)\n \n \n Name\n \n \n Oxford BioMedica plc\n \n \n \n \n b)\n \n \n LEI code\n \n \n 213800S1GVQNXQ15K851\n \n \n \n \n 4.\n \n \n Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n \n \n \n \n a)\n \n \n Description of the financial instrument\n  \n Identification code\n \n \n Ordinary Shares of 50 pence each\n  \n ISIN: GB00BDFBVT43\n \n \n \n \n b)\n \n \n Nature of the transaction\n \n \n Exercise of options\n \n \n \n \n c)\n \n \n Currency\n \n \n GBP - British pound\n \n \n \n \n d)\n \n \n Price(s) and volumes(s)\n \n \n  \n \n \n \n Price(s)\n \n \n Volume(s)\n \n \n \n \n Nil\n \n \n 1,266\n \n \n \n  \n  \n \n \n \n \n e)\n \n \n Aggregated information\n \n -  Aggregate volume\n  \n \n -  Price\n  \n \n -  Aggregated total\...

More updates from Oxford Biomedica Plc